EPIDEMIOLOGY AND MANAGEMENT OF OVARIAN CANCER BASED ON THE CLINICAL EXPERIENCE OF THE SOUTHERN REGION OF UKRAINE

The aim of the study was to evaluate the clinical and epidemiological characteristics of the contingent of patients with RH on the example of the southern region of Ukraine. The research was carried out at the clinical bases of the Department of surgery № 4 with oncology course of the Odessa National Medical University. The standardized indicators of morbidity and mortality for 2007-2016 are analyzed. In addition, an analysis of the survival of 350 patients with stage III-IV in the period 2011-2015 was evaluated. The total one-and three-year survival (TS - total survival); disease free one-and three-year survival (DFS) - disease free survival; FFTF - freedom from treatment failure; event free survival (EFS) - event free survival were estimated. All patients were examined using conventional clinical and laboratory methods according to the standards of diagnosis and treatment of cancer patients, approved by orders of the Ministry of Health of Ukraine No. 140 dated 27.07.1998 and No. 554 dated 17.09.2007. The stage of the tumor process was determined according to the International Classification of TNM 6-th edition (2009). Patients have agreed to use individual clinical data for scientific purposes. The lifetime curves and the values of the surrogate variable were created by the Kaplan-Meyer method. Statistical analysis of the data was performed using the Statistica 10.0 (Dell StatSoft Inc., USA) package; It was established that during the analyzed period (2007-2016) in Odessa oblast there was a gradual decrease in mortality from RV from 5.5 cases per 100,000 population in 2007 to 3.8 in 2016. Dynamics of standardized indicators of morbidity and mortality from the RN shows a probable depopulation and on the effectiveness of the measures used in the region in the primary and secondary prevention of oncopathology. The overall survival of patients with severe forms of URN does not exceed 30 months (28.3±1.4 months). The use of HIPEC technology can increase the overall survival rate to 33.1±1.4 months, DFS to 17.2±1.6 months, FFTF to 17.0±1.6 months, EFS to 16.8±0,9 months, and PFS - up to 16,9±0,8 months.